Henlius Reveals Ambitious Globalization Strategy and Innovation Plans at JPM 2026

Henlius Unveils Its Vision for Globalization at JPM 2026

The 44th J.P. Morgan Healthcare Conference (JPMHC) recently unfolded in San Francisco from January 12 to 15, 2026. This prestigious event served as a platform for Henlius, a prominent player in the biotech industry, to present their forward-thinking strategies and future developmental blueprints. Dr. Jason Zhu, the Executive Director and CEO of Shanghai Henlius Biotech, took the stage to elaborate on the company's 'Globalisation 2.0' initiative.

During his keynote address, Dr. Zhu emphasized Henlius' rapid growth trajectory both domestically and internationally. The company is set to introduce over 20 products globally by the year 2030, with a significant portion aimed at penetrative markets such as the US and Europe, specifically mentioning the launch of more than 15 innovative products in these regions.

A Robust Growth Strategy

Dr. Zhu recounted the impressive milestones achieved under the 'Globalisation 2.0' framework. With multiple product approvals across European and American markets, Henlius has established a resilient integrated operational model worldwide. Dr. Zhu stressed that the company's backing comes from an integrated approach to research and development (R&D), regulatory procedures, and manufacturing capabilities, further bolstered by a sophisticated global clinical and commercialization network.

This organizational strategy has positioned Henlius to maintain its momentum in international business growth. According to Dr. Zhu, the consistent performance from their biosimilar portfolio will enable ongoing investments in innovation. This includes the potential advancement of diverse new medications such as Antibody-Drug Conjugates (ADCs), multi-specific antibodies (multi-Abs), and T-cell engagers (TCEs), which will establish a sustainable global expansion model.

The 2026 Development Roadmap

Henlius did not stop at merely showcasing their broad vision but also provided specific timelines and plans for their core innovative products slated for release in 2026. This spectrum includes key therapies like serplulimab (branded as Hetronifly® in Europe), an anti-PD-1 monoclonal antibody; HLX22, an innovative anti-HER2 monoclonal antibody; HLX43, a PD-L1 ADC; and HLX07, an anti-EGFR monoclonal antibody. These developments indicate Henlius' commitment to addressing various malignant conditions with advanced therapeutic options.

Currently, the company’s preclinical portfolio boasts a diverse range of molecular modalities, with attention primarily focused on solid tumor indications. Their targeted approach encompasses established and emerging cancer biomarkers like PD-(L)1, DLL3, B7-H3, and KAT6A/B, among others. Henlius presents a balanced pipeline that integrates both First-in-Class (FIC) and Best-in-Class (BIC) candidates, alongside swift-follow programs that exhibit heightened clinical viability.

Strategic R&D Architecture

The strategic structuring of Henlius' preclinical assets reflects a deliberate effort to maximize innovation while minimizing risks associated with development. By ensuring a hybrid focus on novel treatment paradigms and established therapeutic standards, they are laying a robust foundation for future investigational trials. Dr. Zhu's vision speaks not just to immediate product launches but also touches on the long-term ideation and execution of next-generation therapies that will revolutionize treatment landscapes globally.

Conclusion

Henlius' unveiling of its 'Globalisation 2.0' strategy and detailed developmental plans marks a significant charge towards enhancing healthcare provision worldwide. As the biotech landscape continues to evolve, Henlius appears poised to become a formidable force, delivering innovative solutions that could potentially forge new paths in the international market. The company's commitment to robust growth, alongside its dedication to advancing biomedical innovation, underscores its pivotal role in shaping the future of healthcare.